treatmentIndication
P113308
predicate
Indicates that a treatment is intended to address, alleviate, or prevent a particular condition, symptom, or medical indication.
All labels observed (16)
| Label | Occurrences |
|---|---|
| combinationIndication | 5 |
| indicationDetail | 3 |
| investigatesIndication | 3 |
| mayBeTreatedWith | 3 |
| therapeuticIndications | 3 |
| AdcetrisIndication | 2 |
| FDAApprovalIndication | 2 |
| approvedIndication | 2 |
| indicationStudied | 2 |
| ponatinibIndication | 2 |
| treatmentIndication canonical | 2 |
| SativexIndication | 1 |
| TukysaIndication | 1 |
| brigatinibIndication | 1 |
| isTargetOfTherapy | 1 |
| tisotumabVedotinIndication | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: treatmentIndication
Generated description
Indicates that a treatment is intended to address, alleviate, or prevent a particular condition, symptom, or medical indication.
Sample triples (34)
| Subject | Object |
|---|---|
| neuroepithelial cyst | symptomatic lesion ⓘ |
| neuroepithelial cyst | progressive enlargement ⓘ |
| Ariad Pharmaceuticals | chronic myeloid leukemia via predicate surface "ponatinibIndication" ⓘ |
| Ariad Pharmaceuticals | Philadelphia chromosome–positive acute lymphoblastic leukemia via predicate surface "ponatinibIndication" ⓘ |
| Ariad Pharmaceuticals | ALK-positive non-small cell lung cancer via predicate surface "brigatinibIndication" ⓘ |
| Truvada | treatment of HIV-1 infection in combination with other antiretrovirals via predicate surface "FDAApprovalIndication" ⓘ |
| Truvada | pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection via predicate surface "FDAApprovalIndication" ⓘ |
| 5q13 (SMN1) | antisense oligonucleotide therapy via SMN2 modulation via predicate surface "isTargetOfTherapy" ⓘ |
| FIREFISH |
Type 1 spinal muscular atrophy
via predicate surface "investigatesIndication"
ⓘ
linked to:
spinal muscular atrophy
|
| FIREFISH | infantile-onset spinal muscular atrophy via predicate surface "investigatesIndication" ⓘ |
| SUNFISH | treatment of spinal muscular atrophy via predicate surface "indicationStudied" ⓘ |
| Tiglutik | treatment of patients with amyotrophic lateral sclerosis to extend survival or time to tracheostomy via predicate surface "indicationDetail" ⓘ |
| Venclexta | CLL with or without 17p deletion via predicate surface "indicationDetail" ⓘ |
| Venclexta | newly diagnosed AML in adults who are 75 years or older or who have comorbidities precluding intensive induction chemotherapy via predicate surface "indicationDetail" ⓘ |
| disruptive mood dysregulation disorder | stimulant medications via predicate surface "mayBeTreatedWith" ⓘ |
| disruptive mood dysregulation disorder | selective serotonin reuptake inhibitors via predicate surface "mayBeTreatedWith" ⓘ |
| disruptive mood dysregulation disorder | atypical antipsychotics via predicate surface "mayBeTreatedWith" ⓘ |
| avelumab | first-line treatment of advanced renal cell carcinoma with axitinib via predicate surface "combinationIndication" ⓘ |
| nivolumab | unresectable or metastatic melanoma via predicate surface "combinationIndication" ⓘ |
| nivolumab | intermediate or poor-risk advanced renal cell carcinoma via predicate surface "combinationIndication" ⓘ |
| nivolumab | malignant pleural mesothelioma via predicate surface "combinationIndication" ⓘ |
| nivolumab | microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer via predicate surface "combinationIndication" ⓘ |
| Techirghiol | rheumatic diseases via predicate surface "therapeuticIndications" ⓘ |
| Techirghiol | dermatological conditions via predicate surface "therapeuticIndications" ⓘ |
| Techirghiol | post-traumatic rehabilitation via predicate surface "therapeuticIndications" ⓘ |
| Seagen | Hodgkin lymphoma via predicate surface "AdcetrisIndication" ⓘ |
| Seagen | systemic anaplastic large cell lymphoma via predicate surface "AdcetrisIndication" ⓘ |
| Seagen | HER2-positive breast cancer via predicate surface "TukysaIndication" ⓘ |
| Seagen | recurrent or metastatic cervical cancer via predicate surface "tisotumabVedotinIndication" ⓘ |
| RE-LY trial | nonvalvular atrial fibrillation via predicate surface "indicationStudied" ⓘ |
| RHINE | diabetic macular edema via predicate surface "investigatesIndication" ⓘ |
| GW Pharmaceuticals | multiple sclerosis spasticity via predicate surface "SativexIndication" ⓘ |
| vigabatrin | infantile spasms in children 1 month to 2 years of age via predicate surface "approvedIndication" ⓘ |
| vigabatrin | refractory complex partial seizures in adults via predicate surface "approvedIndication" ⓘ |